Abiomed, Inc. (ABMD) Tops Q3 EPS by 12c; Boosts Lower-End of FY12 Revs Outlook
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Financial Fact:
Funded research and development: 27K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Funded research and development: 27K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Abiomed, Inc. (NASDAQ: ABMD) reported Q3 EPS of $0.11, $0.12 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $32.2 million versus the consensus estimate of $31.43 million.
Sees FY2012 revenue of $122-$125 million, versus prior guidance of $120-$125 million and the consensus of $123.3 million.
For earnings history and earnings-related data on Abiomed, Inc. (ABMD) click here.
Sees FY2012 revenue of $122-$125 million, versus prior guidance of $120-$125 million and the consensus of $123.3 million.
For earnings history and earnings-related data on Abiomed, Inc. (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Arena Group to rename as Paradium.AI, ticker changing to PAAI
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
